NexTechie BioFlux - The Brief: Oral Obesity Breakthroughs and Major Strategic Acquisitions in Biotech Oncology

Welcome to BioFlux, your deep dive into the breakthroughs transforming modern medicine. This edition highlights the landmark FDA approval of Eli Lilly’s Foundayo, the first daily oral treatment for obesity. This breakthrough was accelerated by the National Priority Voucher program, achieving an unprecedented 50-day review timeline. We also analyze Gilead Sciences’ $5 billion acquisition of Tubulis, signaling major consolidation in the antibody-drug conjugate market. From once-weekly insulins to biologics crossing the blood-brain barrier, we explore how strategic M&A and R&D shifts are redefining chronic disease management and the oncology pipeline.Subscribe to the paid version of NexTechie BioFlux Newsletter on Patreon to gain full access to a Detailed Video and the full Newsletter in English.  NexTechie Premium: http://vip.nextechie.in